Nothing Special   »   [go: up one dir, main page]

CL2008002798A1 - Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer. - Google Patents

Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.

Info

Publication number
CL2008002798A1
CL2008002798A1 CL2008002798A CL2008002798A CL2008002798A1 CL 2008002798 A1 CL2008002798 A1 CL 2008002798A1 CL 2008002798 A CL2008002798 A CL 2008002798A CL 2008002798 A CL2008002798 A CL 2008002798A CL 2008002798 A1 CL2008002798 A1 CL 2008002798A1
Authority
CL
Chile
Prior art keywords
inhibitors
interaction
cancer
mdd2
indol
Prior art date
Application number
CL2008002798A
Other languages
English (en)
Inventor
Sophie Coupa
Bruno Schoentjes
Pierre-Henri Storck
Virginie Sophie Poncelet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38910911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002798(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2008002798A1 publication Critical patent/CL2008002798A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTO DE FÓRMULA (I), DONDE N, M, P, S, T. R1 A R7, R20, X, Y, Q Y Z SON COMO SE DEFINE EN LAS REIVINDICACIONES. COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE PORTADORES ACEPTABLES PARA USO FARMACÉUTICO Y COMO ÍNGREDIENTE ACTIVO UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE DICHO COMPUESTO. USO DE DICHO COMPUESTO COMO INHIBIDORES DE UNA INTERACCIÓN P53-MDM2.<br /> COMBINACIÓN FARMACÉUTICA QUE COMPRENDE UN AGENTE CONTRA EL CÁNCER Y DICHO COMPUESTO. PROCESO PARA PREPARAR DICHO COMPUESTO.<br />  
CL2008002798A 2007-09-21 2008-09-17 Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer. CL2008002798A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07116889 2007-09-21

Publications (1)

Publication Number Publication Date
CL2008002798A1 true CL2008002798A1 (es) 2009-06-05

Family

ID=38910911

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002798A CL2008002798A1 (es) 2007-09-21 2008-09-17 Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.

Country Status (23)

Country Link
US (4) US9573933B2 (es)
EP (1) EP2203440B1 (es)
JP (1) JP5438007B2 (es)
CN (2) CN104761541A (es)
AR (1) AR068627A1 (es)
AT (1) ATE502934T1 (es)
AU (1) AU2008300527B2 (es)
BR (1) BRPI0817223B8 (es)
CA (1) CA2699849C (es)
CL (1) CL2008002798A1 (es)
DE (1) DE602008005784D1 (es)
DK (1) DK2203440T3 (es)
ES (1) ES2363838T3 (es)
HR (1) HRP20110394T1 (es)
JO (1) JO2704B1 (es)
MX (1) MX2010003060A (es)
PA (1) PA8796901A1 (es)
PE (1) PE20090817A1 (es)
RU (1) RU2477724C2 (es)
SI (1) SI2203440T1 (es)
TW (1) TWI434841B (es)
UY (1) UY31349A1 (es)
WO (1) WO2009037308A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MX2011008195A (es) 2009-02-04 2011-09-06 Janssen Pharmaceutica Nv Derivados de indol como agentes anticancer.
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
CN102321034B (zh) * 2011-06-07 2014-08-13 中国人民解放军第二军医大学 硫代苯二氮卓类化合物及其作为药物的用途
EP2771341A4 (en) * 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
ES2410704B1 (es) * 2011-11-28 2014-04-29 Universitat De Barcelona Indoleninas fluoradas útiles para el tratamiento del cáncer.
JP6387013B2 (ja) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｄｍ２阻害薬としての置換されたイミダゾピリジン類
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3558164B1 (en) 2016-12-21 2024-10-09 TriFlo Cardiovascular Inc. Heart valve support device and methods for making the same
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1734401A (en) * 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
PL220721B1 (pl) * 2001-03-29 2015-12-31 Lilly Co Eli Związki będące pochodnymi N-(indolilo-2-etylo) benzyloaminy, kompozycja farmaceutyczna oraz zastosowanie
AU2002357728A1 (en) * 2001-11-09 2003-05-19 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
US7540139B2 (en) * 2004-08-16 2009-06-02 Rowse Hydraulic Rakes Co., Inc. Foldable hay rake
AP2446A (en) * 2004-09-22 2012-08-31 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and P53
WO2006089286A2 (en) * 2005-02-18 2006-08-24 Acadia Pharmaceuticals Inc. Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
WO2009019274A1 (en) * 2007-08-06 2009-02-12 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53

Also Published As

Publication number Publication date
RU2477724C2 (ru) 2013-03-20
AU2008300527B2 (en) 2013-08-29
BRPI0817223B1 (pt) 2020-04-07
TWI434841B (zh) 2014-04-21
US20180263966A1 (en) 2018-09-20
BRPI0817223A2 (pt) 2015-03-10
US20200121667A1 (en) 2020-04-23
ES2363838T3 (es) 2011-08-17
MX2010003060A (es) 2010-04-07
CN101868453A (zh) 2010-10-20
JP2010539220A (ja) 2010-12-16
CA2699849A1 (en) 2009-03-26
DK2203440T3 (da) 2011-06-20
EP2203440A1 (en) 2010-07-07
JO2704B1 (en) 2013-03-03
DE602008005784D1 (de) 2011-05-05
UY31349A1 (es) 2009-03-31
BRPI0817223B8 (pt) 2021-05-25
SI2203440T1 (sl) 2011-07-29
RU2010115765A (ru) 2011-10-27
US9573933B2 (en) 2017-02-21
HRP20110394T1 (hr) 2011-06-30
US11583524B2 (en) 2023-02-21
JP5438007B2 (ja) 2014-03-12
US20100240637A1 (en) 2010-09-23
AU2008300527A1 (en) 2009-03-26
AR068627A1 (es) 2009-11-25
US20170112818A1 (en) 2017-04-27
EP2203440B1 (en) 2011-03-23
WO2009037308A1 (en) 2009-03-26
PE20090817A1 (es) 2009-07-02
TW200930709A (en) 2009-07-16
PA8796901A1 (es) 2009-05-15
CA2699849C (en) 2015-10-27
CN104761541A (zh) 2015-07-08
ATE502934T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
CL2008002798A1 (es) Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201070518A1 (ru) Композиция по уходу за волосами
CO6351786A2 (es) Inkibidores de la cinasa map p38
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
MY153985A (en) Aminotriazole derivatives as alx agonists
CL2015000829A1 (es) Inhibidores de histona desmetilasas
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
PE20090772A1 (es) Derivados de bencimidazol
IN2012DN04940A (es)
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
PE20151055A1 (es) Compuestos triciclicos para inhibir el canal cftr
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
CR9839A (es) Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica